The next controversy in genetic testing: Clinical data as trade secrets?

Robert Cook-Deegan, John M. Conley, James P. Evans, Daniel Vorhaus

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Sole-source business models for genetic testing can create private databases containing information vital to interpreting the clinical significance of human genetic variations. But incomplete access to those databases threatens to impede the clinical interpretation of genomic medicine. National health systems and insurers, regulators, researchers, providers and patients all have a strong interest in ensuring broad access to information about the clinical significance of variants discovered through genetic testing. They can create incentives for sharing data and interpretive algorithms in several ways, including: promoting voluntary sharing; requiring laboratories to share as a condition of payment for or regulatory approval of laboratory services; establishing - and compelling participation in - resources that capture the information needed to interpret the data independent of company policies; and paying for sharing and interpretation in addition to paying for the test itself. US policies have failed to address the data-sharing issue. The entry of new and established firms into the European genetic testing market presents an opportunity to correct this failure.

Original languageEnglish (US)
Pages (from-to)585-588
Number of pages4
JournalEuropean Journal of Human Genetics
Volume21
Issue number6
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Genetic Testing
Information Dissemination
Databases
Insurance Carriers
Access to Information
Medical Genetics
Motivation
Research Personnel
Medicine
Health

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Medicine(all)

Cite this

The next controversy in genetic testing : Clinical data as trade secrets? / Cook-Deegan, Robert; Conley, John M.; Evans, James P.; Vorhaus, Daniel.

In: European Journal of Human Genetics, Vol. 21, No. 6, 01.06.2013, p. 585-588.

Research output: Contribution to journalArticle

Cook-Deegan, Robert ; Conley, John M. ; Evans, James P. ; Vorhaus, Daniel. / The next controversy in genetic testing : Clinical data as trade secrets?. In: European Journal of Human Genetics. 2013 ; Vol. 21, No. 6. pp. 585-588.
@article{cec51deb99c6499f812e54060a9354c8,
title = "The next controversy in genetic testing: Clinical data as trade secrets?",
abstract = "Sole-source business models for genetic testing can create private databases containing information vital to interpreting the clinical significance of human genetic variations. But incomplete access to those databases threatens to impede the clinical interpretation of genomic medicine. National health systems and insurers, regulators, researchers, providers and patients all have a strong interest in ensuring broad access to information about the clinical significance of variants discovered through genetic testing. They can create incentives for sharing data and interpretive algorithms in several ways, including: promoting voluntary sharing; requiring laboratories to share as a condition of payment for or regulatory approval of laboratory services; establishing - and compelling participation in - resources that capture the information needed to interpret the data independent of company policies; and paying for sharing and interpretation in addition to paying for the test itself. US policies have failed to address the data-sharing issue. The entry of new and established firms into the European genetic testing market presents an opportunity to correct this failure.",
author = "Robert Cook-Deegan and Conley, {John M.} and Evans, {James P.} and Daniel Vorhaus",
year = "2013",
month = "6",
day = "1",
doi = "10.1038/ejhg.2012.217",
language = "English (US)",
volume = "21",
pages = "585--588",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The next controversy in genetic testing

T2 - Clinical data as trade secrets?

AU - Cook-Deegan, Robert

AU - Conley, John M.

AU - Evans, James P.

AU - Vorhaus, Daniel

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Sole-source business models for genetic testing can create private databases containing information vital to interpreting the clinical significance of human genetic variations. But incomplete access to those databases threatens to impede the clinical interpretation of genomic medicine. National health systems and insurers, regulators, researchers, providers and patients all have a strong interest in ensuring broad access to information about the clinical significance of variants discovered through genetic testing. They can create incentives for sharing data and interpretive algorithms in several ways, including: promoting voluntary sharing; requiring laboratories to share as a condition of payment for or regulatory approval of laboratory services; establishing - and compelling participation in - resources that capture the information needed to interpret the data independent of company policies; and paying for sharing and interpretation in addition to paying for the test itself. US policies have failed to address the data-sharing issue. The entry of new and established firms into the European genetic testing market presents an opportunity to correct this failure.

AB - Sole-source business models for genetic testing can create private databases containing information vital to interpreting the clinical significance of human genetic variations. But incomplete access to those databases threatens to impede the clinical interpretation of genomic medicine. National health systems and insurers, regulators, researchers, providers and patients all have a strong interest in ensuring broad access to information about the clinical significance of variants discovered through genetic testing. They can create incentives for sharing data and interpretive algorithms in several ways, including: promoting voluntary sharing; requiring laboratories to share as a condition of payment for or regulatory approval of laboratory services; establishing - and compelling participation in - resources that capture the information needed to interpret the data independent of company policies; and paying for sharing and interpretation in addition to paying for the test itself. US policies have failed to address the data-sharing issue. The entry of new and established firms into the European genetic testing market presents an opportunity to correct this failure.

UR - http://www.scopus.com/inward/record.url?scp=84883100680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883100680&partnerID=8YFLogxK

U2 - 10.1038/ejhg.2012.217

DO - 10.1038/ejhg.2012.217

M3 - Article

C2 - 23150081

AN - SCOPUS:84883100680

VL - 21

SP - 585

EP - 588

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 6

ER -